| Literature DB >> 27378659 |
Mauro Gori1, Maurizio Volterrani2, Massimo Piepoli3, Michele Senni4.
Abstract
Sacubritil∗valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies. Copyright ÂEntities:
Keywords: ARNi; Angiotensin receptor–neprilysin inhibitor; Heart failure; LCZ696
Mesh：
Substances：
Year: 2016 PMID： 27378659 DOI： 10.1016/j.ijcard.2016.06.083
Source DB: PubMed Journal: Int J Cardiol ISSN： 0167-5273 Impact factor: 4.164